Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV).
D000276:Adjuvants, Immunologic / Q000191:economics* / Q000627:therapeutic use; D000293:Adolescent; D000890:Anti-Infective Agents / Q000191:economics / Q000627:therapeutic use; D001419:Bacteria; D002457:Cell Extracts / Q000191:economics* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003139:Common Cold / Q000188:drug therapy / Q000191:economics* / Q000517:prevention & control*; D016208:Databases, Factual; D003661:Decision Support Techniques; D005602:France; D017048:Health Care Costs; D006760:Hospitalization / Q000191:economics; D006801:Humans; D018803:Models, Economic; D012008:Recurrence; D012307:Risk Factors; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D000890:Anti-Infective Agents; D002457:Cell Extracts; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates